Loading...
01/11 04:43
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary and Q&A indicate a positive sentiment. The company shows strong revenue growth guidance across all segments, improving gross margins, and a strategic focus on AI synergies. Despite some guidance below expectations, management remains optimistic about long-term growth, especially in NGS and Biopharma. The expected breakeven point for adjusted EBITDA and new product launches further support a positive outlook. The market cap suggests a moderate reaction, leading to a predicted positive stock price movement of 2% to 8% over the next two weeks.
Revenue for Q4 2025 $99 million, an increase of 17% year-over-year. This growth was attributed to strong demand across all product lines and the addition of new products and solutions.
Revenue for fiscal year 2025 $376.6 million, a growth of 20% over fiscal 2024. This was driven by leveraging proprietary silicon chip-based technology and expanding market share.
Gross margin for Q4 2025 51.3%, reflecting an improvement due to higher volume and continuous margin improvement efforts.
Gross margin for fiscal year 2025 50.7%, compared to 42.6% in fiscal 2024. This improvement was due to leveraging fixed costs with higher volume and a focus on margin improvement over the last two years.
SynBio revenue for Q4 2025 $39.5 million, an increase of 17% year-over-year. Growth was led by the Express portfolio and AI-enabled drug discovery projects.
SynBio revenue for fiscal year 2025 $145 million, a 17% increase compared to $123.5 million in fiscal 2024. Growth was driven by the Express portfolio and AI-enabled drug discovery.
NGS revenue for Q4 2025 $53 million, a growth of 16% year-over-year. This was driven by diagnostic customers' clinical assays and population genetics wins.
NGS revenue for fiscal year 2025 $208.1 million, a growth of 23% year-over-year. Growth was attributed to diagnostic workflows and adoption of new sequencing platforms.
Biopharma revenue for Q4 2025 $6.4 million, an increase of 22% year-over-year. Growth was driven by AI-driven drug discovery projects and integration with SynBio.
Biopharma revenue for fiscal year 2025 $23.5 million, a growth of 15% year-over-year. Growth was supported by AI-driven drug discovery and customer reliance on Twist for critical experiments.
Americas revenue for Q4 2025 $57.3 million, a growth of 9% year-over-year. Growth was driven by strong demand across product lines.
EMEA revenue for Q4 2025 $34.6 million, a growth of 35% year-over-year. This was attributed to exceptional demand in the region.
APAC revenue for Q4 2025 $7.2 million, a growth of 9% year-over-year. Growth was driven by demand across product lines.
Adjusted EBITDA for Q4 2025 Loss of $7.8 million, an improvement of $9.2 million compared to Q4 2024. This was due to improved gross margins and cost management.
Adjusted EBITDA for fiscal year 2025 Loss of $46.9 million, an improvement of $46.6 million compared to fiscal 2024. This was driven by improved gross margins and cost management.
SynBio Revenue Growth: SynBio revenue increased to $39.5 million, up 17% year-over-year, driven by the Express portfolio and AI-enabled drug discovery projects.
NGS Revenue Growth: NGS revenue grew to $53 million, a 16% increase year-over-year, supported by diagnostic customers' clinical assays and new product introductions like FlexPrep sequencing workflow.
Biopharma Revenue Growth: Biopharma revenue reached $6.4 million, a 22% increase year-over-year, with significant contributions from AI-driven drug discovery projects.
MRD Express Product: Twist is finalizing an express product for minimal residual disease (MRD) with a 12-hour turnaround, expected to launch in early 2026.
AI-Driven Drug Discovery: Orders from AI-enabled drug discovery projects grew by over $25 million compared to fiscal 2024, highlighting a significant market expansion.
Population Genetics and AgBio: Two significant wins in population genetics using FlexPrep sequencing workflow, targeting a $500 million SNP microarray market.
Gross Margin Improvement: Gross margin improved to 51.3% for the quarter and 50.7% for the year, up from 42.6% in fiscal 2024, driven by higher volumes and process improvements.
Geographic Revenue Distribution: EMEA revenue grew by 35% year-over-year, while Americas and APAC saw 9% growth each.
New Revenue Reporting Structure: Starting fiscal 2026, revenue will be reported under new categories: Therapeutics, Diagnostics, Industrial and Applied Markets, Academic Research and Government, and Global Supply Partners.
Focus on AI and Biopharma Integration: Increased integration between SynBio and Biopharma to serve AI-driven drug discovery and traditional therapeutic discovery.
Market Conditions: The company faces challenges in maintaining growth amidst competitive pressures and evolving market demands, particularly in the SynBio and Biopharma sectors. The rapid expansion of AI-enabled drug discovery creates opportunities but also intensifies competition.
Regulatory Hurdles: The company operates in highly regulated industries, including diagnostics and therapeutics, which may pose compliance challenges and delays in product approvals.
Supply Chain Disruptions: While the company claims to have future-proofed its supply chain, any disruptions could impact its ability to deliver products, especially for time-sensitive applications like cancer diagnostics.
Economic Uncertainties: Global economic conditions, including potential slowdowns in key markets like the Americas and EMEA, could impact revenue growth and customer spending.
Strategic Execution Risks: The company’s ambitious growth plans, including new product launches and market expansions, require flawless execution. Any missteps could delay revenue realization and impact profitability.
Customer Dependency: A significant portion of revenue comes from a few large customers, particularly in the NGS segment. Any changes in purchasing behavior or delays in commercial scaling by these customers could impact financial performance.
Technological Advancements: The company’s reliance on proprietary technology for competitive advantage necessitates continuous innovation. Failure to keep pace with technological advancements could erode market share.
Revenue Growth: The company expects total revenues of $425 million to $435 million for fiscal 2026, representing growth of approximately 13% to 15.5% year-over-year.
DNA Synthesis and Protein Solutions Revenue: Revenue is projected to be $194 million to $199 million, reflecting growth of 15% to 18% over fiscal 2025, driven by strong demand from AI discovery customers.
NGS Applications Revenue: Revenue is expected to be $231 million to $236 million, representing growth of 11% to 13.5% over fiscal 2025. Growth is anticipated to accelerate to 20% year-over-year by Q4, driven by a large diagnostic customer ramping commercial volume in Q2.
Gross Margin: Gross margin is expected to exceed 52% for fiscal 2026, building on the 50% margin achieved in fiscal 2025.
Adjusted EBITDA: The company aims to achieve adjusted EBITDA breakeven by the fourth quarter of fiscal 2026.
Minimal Residual Disease (MRD) Product: A new express product for MRD is expected to be introduced commercially in early calendar 2026, with significant growth anticipated in late 2026 into 2027.
AI-Driven Drug Discovery: The company sees strong demand from AI-driven drug discovery customers, with significant revenue contributions expected in fiscal 2026.
NGS Product Growth: Growth is expected across all areas of the NGS portfolio in 2026, including RNA-Seq workflows and diagnostic tests.
New Revenue Reporting Categories: Starting in fiscal 2026, revenue will be reported under new categories: Therapeutics, Diagnostics, Industrial and Applied Markets, Academic Research and Government, and Global Supply Partners.
The selected topic was not discussed during the call.
The earnings call summary and Q&A indicate a positive sentiment. The company shows strong revenue growth guidance across all segments, improving gross margins, and a strategic focus on AI synergies. Despite some guidance below expectations, management remains optimistic about long-term growth, especially in NGS and Biopharma. The expected breakeven point for adjusted EBITDA and new product launches further support a positive outlook. The market cap suggests a moderate reaction, leading to a predicted positive stock price movement of 2% to 8% over the next two weeks.
The earnings call highlights strong revenue growth across multiple segments, particularly in NGS and healthcare. Despite some challenges like customer pushouts and SynBio weakness due to tough comparisons, the overall sentiment remains positive with optimistic future guidance. The company expects to reach adjusted EBITDA breakeven by 2026, and gross margins are improving. The Q&A section reveals analysts' confidence in the company's strategic direction and growth potential, especially with new product introductions and international expansion efforts. Given the market cap, a positive reaction (2% to 8%) is expected over the next two weeks.
The earnings call indicates several concerning factors: a missed EPS expectation, increased operational costs, and ongoing financial challenges. While there is revenue growth and improved gross margins, the lack of a shareholder return plan and unclear guidance on tariffs and R&D reinvestment pose risks. The market's uncertainty, especially with policy shifts, further compounds these issues. Given the company's small market cap, these negative elements could lead to a stock price decrease in the short term.
Despite risks like market conditions and tariffs, Twist shows strong financial performance with 23% revenue growth and improved gross margins. The spin-off of Atlas Data Storage reduces cash burn and enhances EBITDA. Positive guidance and strategic reinvestment plans further bolster sentiment. The market cap suggests moderate sensitivity to these developments, leading to a positive stock price prediction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
